Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Sales (2017 - 2025)

UroGen Pharma (URGN) has disclosed Return on Sales for 9 consecutive years, with 0.7% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 83.0% year-over-year to 0.7%, compared with a TTM value of 1.4% through Dec 2025, up 1.0%, and an annual FY2025 reading of 1.4%, up 1.0% over the prior year.
  • Return on Sales was 0.7% for Q4 2025 at UroGen Pharma, up from 1.21% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.7% in Q4 2025 and bottomed at 3.46% in Q1 2021.
  • Average Return on Sales over 5 years is 1.69%, with a median of 1.61% recorded in 2022.
  • The sharpest move saw Return on Sales surged 697465bps in 2021, then tumbled -53bps in 2025.
  • Year by year, Return on Sales stood at 1.76% in 2021, then rose by 9bps to 1.6% in 2022, then surged by 31bps to 1.11% in 2023, then tumbled by -38bps to 1.53% in 2024, then soared by 54bps to 0.7% in 2025.
  • Business Quant data shows Return on Sales for URGN at 0.7% in Q4 2025, 1.21% in Q3 2025, and 2.06% in Q2 2025.